Medicare Review Questions Prostate Cancer Screenings
A review of Medicare spending finds nearly 150 million dollars are spent each year on prostate cancer screenings for men 75 years and older, even though the tests have little benefit for men in that age group.
Many prostate cancers are slow-growing and unlikely to ever become harmful.
Researchers at Yale also found the costs vary widely according to region depending on how many follow-up procedures are ordered.
The study concludes that many older men who are diagnosed with early stage prostate cancer may end up receiving therapy that could be harmful and costly.